Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma

Assiut University50 enrolled

Overview

Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Urinary Bladder Cancer

Interventions

ChemoradiationRADIATION

Hypofractionated radiotherapy with concurrent Gemcitabine

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Pathologically confirmation of transitional cell carcinoma . Non metastatic invasive bladder cancer (TNM0) Any age group ≥ 18 years. Non pregnant female patients. Exclusion Criteria: \- Other pathology than Transitional cell carcinoma Metastatic Patient Age less than 18 years

Outcomes

Primary Outcomes

Response to hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer

Estimate Disease free survival .

Time frame: baseline

Central Contacts

Esraa Mostafa Abdelzahir, Master degree

CONTACT

+201093534631 Essra.mostafa1993@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.